Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(0)
•••
Comment by PoorOpinionon Apr 17, 2018 8:23pm
222 Views
Post# 27901642

RE:RE:RE:RE:RE:RE:RE:RE:RE:example

RE:RE:RE:RE:RE:RE:RE:RE:RE:example
Edcando wrote: I may be misunderstanding this thread, but if I'm not, we are in great shape regardless. I think it's more likely they'll do a licensing deal (or several smaller regional ones/or a JV)) first for ATB-346. The upfront payment (s) will be more than enough for phase 3 (as that will be the minimum requirement for allowing someone in this early). This approach imo will lead to a higher sp/valuation with several stepping stone catalysts rather than just one whole buyout (unless they're prepared to pay dearly )


That's how I see it. The smaller regional deals will be nice but the US/EU deal will set the valuation for the company. Hopefully the partner is big enough to provide some weight for the stock and make it less of a traders plaything. There's surely still plenty of upside to come from the main licencing deal from where we are today, and as you say the full value is realised in steps as(if) it meets the remaining major milestones. 

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities